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Objectives. The aim of this study was to assess the cardiovas-
cular effects of BAY y 5959, a calcium promoter modulating
myocardial calcium channels, in the presence or absence of
congestive heart failure.
Background. There is still a clinical need for short-term
administration of intravenous positive inotropes. BAY y 5959 was
developed as a new approach to increase myocardial performance
by selectively enhancing calcium influx in the myocytes.
Methods. Forty-one patients (21 without and 20 with congestive
heart failure) were studied in an open label, dose-ranging study.
Hemodynamic variables (including left ventricular [LV] angiog-
raphy) and plasma samples were obtained at baseline and after
20 min of intravenous infusion of BAY y 5959 at doses ranging
from 0.25 to 4.5 mg/kg body weight per min.
Results. In both study groups, BAY y 5959 produced dose-
dependent increases in the indexes of inotropic state, without
affecting isovolumetric relaxation rate. The magnitude of the
response was comparable in patients with or without heart failure
(average 38% increase in maximal first derivative of LV pressure
[dP/dt max] at plasma levels of 100 mg/liter). BAY y 5959 also
induced mild but statistically significant bradycardia and signif-
icantly decreased end-systolic volume while producing a leftward
shift of the pressure-volume loop. Mean aortic pressure was
unaffected at doses up to 3.0 mg/kg per min, and cardiac index
improved in patients with heart failure at doses of 2.0 mg/kg per
min (123%, p < 0.05). However, at a dose of 4.5 mg/kg per min,
mean aortic pressure and LV systolic wall stress increased,
suggesting systemic vasoconstriction. The QT interval was also
prolonged significantly at most doses.
Conclusions. BAY y 5959 exhibits positive inotropic effects in
patients with and without heart failure. The optimal response—
combining bradycardia, reduced preload and improved cardiac
output—appeared to be achieved at a dose of ;2.0 mg/kg per min.
The impact of QT prolongation with regard to potential antiar-
rhythmic or proarrhythmic effects is unclear at this time.
(J Am Coll Cardiol 1997;30:1751–7)
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Although the prolonged use of positive inotropic agents in the
treatment of congestive heart failure has been seriously ques-
tioned because of an increase in mortality (1,2), the short-term
administration of intravenous positive inotropes remains a
major therapeutic tool in several clinical situations, such as
myocardial depression after cardiac bypass surgery or as a
bridge in patients with severe heart failure on waiting list for
transplantation. The most commonly used agents, such as
catecholamines or phosphodiesterase inhibitors, have many
potential drawbacks, including tachycardia, beta-receptor
down-regulation and ventricular arrhythmias (1–3). However,
it is not yet clear whether the excess mortality is secondary to
some direct pharmacologic action of these drugs (i.e., in-
creased intracellular cyclic adenosine monophosphate) or
whether they are an unavoidable consequence of inotropic
stimulation in this setting (i.e., through energy imbalance or
ischemia). Accordingly, new inotropic mechanisms such as
calcium sensitization of the contractile proteins or an increase
in intracellular calcium availability have recently been investi-
gated. However, earlier attempts to increase myocardium
calcium influx by opening the voltage dependent L-type cal-
cium channel were plagued by severe vasoconstriction as well
as by proarrhythmia in various experimental models (4).
Recently, new chemical entities with dihydropyridine struc-
ture have been identified that show calcium agonistic proper-
ties on cardiomyocytes but have little or no functional effect on
L-type calcium channels in vascular smooth muscle cells
despite their high affinity binding to calcium channels in both
tissues. A lead compound in this series, BAY y 5959 [(2)-R-
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isopropyl 2-amino-5-cyano-1,4-dihydro-6-methyl-4-(3-phenyl-
quinoline-5-yl)-pyridine-3-carboxylate] is modulating the open
and close time of single calcium channels in myocytes. Due to
the larger increase in mean open times, the overall effect of
BAY y 5959 is increased calcium entry into the cells and
prolongation of the action potential, two properties resulting in
a positive inotropic effect in various in vitro models (5). These
compounds are cardioselective because they only prolong the
mean open times of L-type calcium channels at depolarizations
beyond 220/210 mV, levels readily achieved during the car-
diac action potential but rarely in vascular smooth muscle cells.
These promising pharmacologic properties, differing signifi-
cantly from those of other inotropic agents and coupled with a
greater selectivity for the myocytes than for the vascular
smooth muscle cells, warranted clinical evaluation of the
compound. The present study was therefore undertaken to
assess the effects of BAY y 5959 on myocardial contractility,
mean arterial pressure and electrocardiographic (ECG) in-
dexes in patients with varying degrees of left ventricular (LV)
dysfunction.
Methods
Patient selection. For safety reasons, this evaluation was
performed open labeled, starting from low doses and increas-
ing to higher doses when the safety of the previous dose level
had been established. Moreover, because the responsiveness to
inotropes and the risk of proarrhythmia differ substantially
between patients with congestive heart failure and patients
with normal or preserved LV function, the study was per-
formed in two steps—study 1, an evaluation in 21 patients with
ischemic heart disease and no or only mild heart failure, and
study 2, an evaluation in 20 patients with moderate to severe
New York Heart Association [NYHA] functional class III to
IV heart failure.
Demography. Study 1. This study recruited 21 men with
coronary artery disease admitted for diagnostic cardiac cathe-
terization. Their ages ranged from 42 to 74 years (mean 6 SD
62 6 8); 14 men had had a previous myocardial infarction.
Twelve were in NYHA functional class I and 9 were in class II.
Fourteen suffered from angina pectoris.
Study 2. This study enrolled 17 men and 3 women with
congestive heart failure ranging in severity from moderate
(NYHA class III, n 5 11) to severe (NYHA class IV, n 5 9).
Their ages ranged from 49 to 74 years (mean 62 6 7). Four
patients suffered from idiopathic dilated cardiomyopathy, 2
from alcoholic cardiomyopathy, 13 from ischemic cardiomyop-
athy (including 10 with one or more previous myocardial
infarctions) and 1 from persistent heart failure after mitral
valve replacement.
All patients gave written informed consent, and both stud-
ies were approved by the local institutional review board. All
patients were in sinus rhythm, and all cardiovascular drugs,
except angiotensin-converting enzyme inhibitors and diuretic
agents, had been discontinued $24 h before the study.
Study protocol. Left heart catheterization was performed
by way of the femoral route, as described in detail previously
(6). After diagnostic coronary angiography, an 8F pigtail Millar
micromanometer was advanced into the LV, for LV pressure
recording and contrast material injection. Arterial pressure
was measured in the femoral artery and a standard ECG lead
(D1) was continuously recorded. After baseline hemodynamic
and angiographic measurements were obtained, BAY y 5959
was infused intravenously for 20 min before angiographic and
hemodynamic data collection was repeated. The doses in study
1 were 0.25, 0.50, 1.0, 2.0 and 3.0 mg/kg per min, respectively,
with four patients completing each dose. In one patient
receiving the 2.0-mg/kg per min dose, infusion was stopped
after 15 min because of angina pectoris and the patient was
withdrawn from the study. The doses in study 2 were 1.0, 2.0,
3.0 and 4.5 mg/kg per min, respectively, with five patients per
dose. No other adverse events were observed during or after
infusion. Plasma samples for assay of BAY y 5959 were also
obtained, in study 1, at 20, 30, 45 to 60 min and 4 to 6 h after
drug infusion, and in study 2, at 20, 30, 40, 50, 60 min and 4 to
6 h after drug infusion.
Data analysis. Left ventriculography together with the
ECG and pressure signals were digitized on-line (DVI Philips,
50 frames/s) and processed off-line (APU Philips, Philips
Electronic Instruments). The ventricular silhouettes were dig-
itized frame by frame on a video screen after mask substrac-
tion; the computer system derived the correction factor for
X-ray magnification and calculated volumes every 20 ms by
applying Simpson’s rule. Wall thickness at the LV equator was
traced on the last unmasked diastolic frame and was computed
for subsequent frames assuming a constant LV mass. Midwall
circumferential stress was calculated with the formula of
Mirsky (7). Mean systolic wall stress was obtained by averaging
data from the start to the end of ejection, and mean diastolic
wall stress was obtained by averaging data from the start of
diastolic filling to end-diastole. Volume data were normalized
by using body surface area, and pressure-volume loops were
plotted for each patient. The angiographic cardiac index was
calculated as
Angiographic stroke volume index 3 Heart rate.
Other hemodynamic data were also continuously digitized
on-line every 2 ms and processed off-line to derive the isovolu-
metric indexes of inotropic state—maximal first derivative of
Abbreviations and Acronyms
dP/dt 5 first derivative of left ventricular pressure
(dP/dt)/DP40 5 first derivative of left ventricular pressure measured
and normalized at a developed pressure of 40 mm Hg
dP/dt max 5 maximal first derivative of left ventricular pressure
ECG 5 electrocardiographic
LV 5 left ventricle (ventricular)
LVEDP 5 left ventricular end-diastolic pressure
NYHA 5 New York Heart Association
QTc 5 corrected QT interval
T1 5 time constant of early isovolumetric pressure decrease
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LV pressure (dP/dt max) and first derivative of left ventricular
pressure (dP/dt) measured and normalized at a developed
pressure of 40 mm Hg [(dP/dt)/DP40 (8)]—and the time
constant of early isovolumetric pressure decrease, T1 (9).
Systemic vascular resistance was calculated as
(Mean aortic pressure/Angiographic cardiac output) 3 80.
Pharmacokinetic evaluation. BAY y 5959 plasma concen-
trations were determined by a validated liquid chromatogra-
phy/mass spectrometry assay. The limit of quantification was
0.1 m/liter. The coefficients of variation were ,10% in the
calibration range (0.1 to 100 mg/liter).
For data evaluation a population approach was chosen,
using the Nonmem version IV level 2.1 program for model
building and subsequent variable estimation. The final popu-
lation pharmacokinetic model to describe the data was an open
two-compartment body model with first-order elimination
from the central compartment. The final population pharma-
codynamic model was a linear relation between BAY y 5959
concentrations, linked by way of an additional effect site
compartment to the central compartment to compensate the
equilibrium delay indicated by the observed counterclockwise
hysteresis, and the contractility index dP/dt max (percent
change from baseline) as effect variable. Individual empiric
Bayesian estimates (e.g. for clearance) were obtained from the
final population pharmacokinetic model using the “posthoc”
feature of the Nonmem program. These estimates were plotted
against dose to check for dose-proportional pharmacokinetic
behavior and against age and baseline cardiac index to search
for a possible relation (10).
Statistical analysis. Because the primary objective of this
open study was safety, and because it did not include a
placebo-controlled group, each group was analyzed separately,
and the p values presented (based on paired t test calculations)
are considered explorative. To account for multiple compari-
sons, the t test in each group was performed only if a global test
showed a statistically significant change from baseline for the
selected variable regardless of the group selected. This global
test was performed by using an analysis of variance. Because of
the multiple comparisons and relatively small sample sizes, the
possibility of a type I error needs to be considered. Thus, for a
more conservative evaluation of the effects, one might rely only
on the overall comparisons and use the Bonferroni correction.
Even with this conservative approach, all values ,0.001 in
Tables 1 to 3 would remain statistically significant.
Results
Study 1. Tables 1 and 2 summarize the hemodynamic and
angiographic changes. Overall, BAY y 5959 infusion at doses
ranging from 0.25 to 3.0 mg/kg per min decreased heart rate
and slightly increased stroke volume index with minimal effects
on LV end-diastolic pressure, LV systolic pressure, mean
aortic pressure or angiographic cardiac index (3.67 6 0.84 to
3.40 6 0.85 literszmin21zm22; p 5 NS). The indexes of
inotropic state increased and the increases were significant at
doses $2.0 mg/kg per min, without affecting the time constant
of isovolumetric pressure decrease. Despite the dose-dependent
bradycardia, averaging 211.9 beats/min at 3.0 mg/kg per min,
end-diastolic volume index tended to decrease and there was a
significant reduction in end-systolic volume index at the high-
est dose. This reduction in end-systolic volume was accompa-
nied by a leftward shift of the pressure-volume loop (Fig. 1),
further supporting the conclusion that myocardial contractility
had increased. At these dose levels, afterload estimated either
as mean systolic wall stress (210 kdynes/cm2; p 5 NS), as
mean aortic pressure (20.5 mm Hg; p 5 NS) or as systemic
vascular resistance (1,283 6 390 to 1,385 6 381 dyneszszcm25;
p 5 NS) did not change. The corrected QT interval (QTc)
tended to increase at doses above 0.25 mg/kg per min but, as
shown in Table 1 and Fig. 2, the relation between plasma
concentration of BAY y 5959 and changes in dP/dtmax was
more linear than with the QTc prolongation, which reached a
plateau earlier. In addition, both relations exhibited hysteresis.
Study 2. The effects of BAY y 5959 on changes in heart
rate and indexes of inotropic state in patients with moderate to
severe heart failure paralleled those observed in study 1
(Tables 1 and 3, Fig. 3), but the overall decrease in LVEDP
was more marked than in study 1. Stroke volume index
increased significantly at the three highest dose levels but
Table 1. Hemodynamic Data: Study 1
Mean
Baseline
(n 5 20)
D Dose 0.25
(n 5 4)
D Dose 0.50
(n 5 4)
D Dose 1.0
(n 5 4)
D Dose 2.0
(n 5 4)
D Dose 3.0
(n 5 4)
D Global
(n 5 20)
HR (beats/min) 69.5 6 8.6 25.0 6 7.4 25.6 6 3.7 21.6 6 7.6 27.0 6 1.8† 211.9 6 4.5* 26.2 6 6.0‡
LVEDP (mm Hg) 23.7 6 5.7 22.4 6 2.2 22.7 6 1.4* 1.1 6 2.0 23.1 6 4.8 24.2 6 4.1 22.3 6 3.4†
LVSP (mm Hg) 160.0 6 20.5 21.1 6 4.3 22.3 6 6.4 12.2 6 3.2 2.1 6 10.7 2.6 6 2.5 2.7 6 7.6
Mean AoP (mm Hg) 112.0 6 13.2 25.5 6 5.0 24.3 6 5.6 6 6 3.4 21.0 6 2.0 20.5 6 7.9 20.8 6 6.1
dP/dt max (mmHg/s) 1,612 6 180 16 6 72 219 6 250 258 6 96* 322 6 187* 436 6 147† 203 6 232‡
(dP/dt)/DP40 (s21) 23.7 6 2.8 0.7 6 1.5 1.2 6 1.9 3.1 6 2.0 5.2 6 3.3* 7.9 6 1.8† 3.6 6 3.4‡
T1 (ms) 53.5 6 7.7 0.7 6 1.8 2.7 6 6.4 1.5 6 2.0 0.0 6 6.1 1.7 6 6.3 1.3 6 4.5
QTc (ms) 435 6 28 26 6 23 18 6 8* 15 6 34 57 6 18† 31 6 36 23 6 31†
*p , 0.05. †p , 0.01. ‡p , 0.001. Data are expressed as mean value 6 SD. AoP 5 aortic pressure; dP/dt 5 first derivative of left ventricular pressure;
(dP/dt)/DP40 5 dP/dt measured and normalized at a developed pressure of 40 mm Hg; dP/dt max 5 maximal dP/dt; HR 5 heart rate; LVEDP 5 left ventricular
end-diastolic pressure; LVSP 5 left ventricular systolic pressure; T1 5 time constant of early isovolumetric pressure decrease; QTc 5 corrected QT interval.
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because of the bradycardia, the changes in cardiac index were
less pronounced. Angiographic cardiac index tended to in-
crease at doses of 2.0 (123 6 13%; p , 0.05), 3.0 (111 6 6%;
p 5 NS) and 4.5 (18 6 13%; p 5 NS) mg/kg per min. There
was also some evidence of unfavorable hemodynamic effects
when the dose was increased from 3.0 to 4.5 mg/kg per min.
Indeed, at the highest dose and despite further increase in
inotropic state, LV systolic pressure, mean aortic pressure and
mean systolic wall stress all tended to increase, as did systemic
vascular resistance (15 6 13% at 4.5 mg/kg per min vs. 214 6
9% and 27 6 11% at the dose of 2.0 and 3.0 mg/kg per min,
respectively), suggesting that BAY y 5959 could exert some
vasoconstriction at the highest dose level.
Pharmacokinetic measurements. There was a good corre-
lation between total dose administered and total exposure, and
no significant difference in pharmacokinetics was detected
between the patients of studies 1 and 2 (Fig. 4). Neither age
nor baseline cardiac index had an influence on BAY y 5959
pharmacokinetics. A population pharmacokinetic/pharmaco-
dynamic modeling combining the data from the two studies
supports a linear relation between BAY y 5959 plasma con-
centrations and dP/dt max for the observed concentration
range of up to 200 mg/liter. A BAY y 5959 steady state
concentration of ;100 mg/liter will result in a 38% change in
dP/dt max.
Table 2. Angiographic Data
Study 1
Mean
Baseline
(n 5 20)
D Dose 0.25
(n 5 4)
D Dose 0.50
(n 5 4)
D Dose 1.0
(n 5 4)
D Dose 2.0
(n 5 4)
D Dose 3.0
(n 5 4)
D Global
(n 5 20)
EF (%) 47 6 12 4.5 6 5.3 5.3 6 3.1* 10.5 6 12.8 7.0 6 10.8 11.3 6 13.0 7.7 6 9.2†
EDVI (ml/m2) 114 6 20 2.5 6 4.8 0.5 6 7.3 23.8 6 8.0 23.8 6 9.4 210.5 6 12.9 23.0 6 9.1
ESVI (ml/m2) 61 6 22 22.8 6 4.1 24.8 6 6.5 213.5 6 11.7 210.5 6 9 217.0 6 9.6* 29.7 6 9.4‡
SVI (ml/m2) 53 6 7 5.3 6 2.2 5.3 6 3.2 9.7 6 5.9 6.7 6 5.0 6.5 6 4.5 6.7 6 4.5
MSS (kdynes/cm2) 326 6 76 27 6 11 6 6 33 233 6 18 237 6 32 210 6 54 216 6 34*
MDS (kdynes/cm2) 63 6 29 210 6 8 28 6 12 28 6 6 221 6 24 229 6 4‡ 215 6 14‡
Study 2
Mean
Baseline
(n 5 20)
D Dose 1.0
(n 5 5)
D Dose 2.0
(n 5 5)
D Dose 3.0
(n 5 5)
D Dose 4.5
(n 5 5)
D Global
(n 5 20)
EF (%) 17 6 8 2.6 6 1.5* 4.4 6 5.9 6.6 6 4.8* 12.8 6 10.5 6.6 6 7.2‡
EDVI (ml/m2) 203 6 54 26.4 6 10.3 26.6 6 22.2 28.8 6 10.7 23.8 6 15.5 26.4 6 14.3
ESVI (ml/m2) 170 6 55 210.2 6 7.1* 212.2 6 17.1 219.2 6 14.5* 224.4 6 19.1* 216.5 6 15.1‡
SVI (ml/m2) 33 6 17 3.8 6 3.3 5.6 6 4.2* 10.4 6 5.0* 20.6 6 7.2* 10.1 6 6.7†
MSS (kdynes/cm2) 342 6 57 217 6 31 11 6 60 4 6 66 20 6 63 4 6 54
MDS (kdynes/cm2) 121 6 40 227 6 25 222 6 23 231 6 19* 218 6 31 225 6 24‡
*p , 0.05. †p , 0.01. ‡p , 0.001. Data are expressed as mean value 6 SD. EDVI 5 end-diastolic volume index; EF 5 ejection fraction; ESVI 5 end-systolic volume
index; MDS 5 mean diastolic wall stress; MSS 5 mean systolic wall stress; SVI 5 stroke volume index.
Figure 1. Typical changes in LV pressure–volume loop after infusion
of BAY y 5959 at a dose of 3.0 mg/kg per min in a patient with
preserved LV function. There was a leftward shift in end-systolic
pressure–volume data and a slight downward shift of the diastolic
pressure–volume data.
Figure 2. Typical relation between plasma concentration and dP/dt
max or QTc prolongation during and immediately after cessation of
infusion of BAY y 5959 at a dose of 3.0 mg/kg per min. Although both
relations exhibited some hysteresis, dP/dt max increased almost lin-
early with plasma concentration, whereas QTc prolongation main-
tained a plateau (same patient as in Fig. 1). l 5 liter.
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Discussion
The aim of the study was to explore the tolerability and
hemodynamic effects of the new calcium promoter BAY y 5959
in the presence or absence of congestive heart failure. Overall,
the drug was well tolerated during and after the infusion
period. Only one patient, in study 1, with a history of anterior
myocardial infarction 10 years before the study and recent
onset of chest pain, was withdrawn prematurely because of
typical angina after 15 min of infusion. Diagnostic coronary
arteriography and baseline ventriculography had revealed
three-vessel disease and an ejection fraction of 37%. The
relation between angina and the drug infusion is difficult to
interpret, but a contribution of BAY y 5959 cannot be ruled
out. This patient recovered fully. No other adverse events
attributable to the study drug were noted up to 30 days after
study.
Three other aspects of the effects of BAY y 5959 are also
worth reviewing in detail: the inotropic and lusitropic actions,
the overall effect on LV pump function and effects on heart
rate and QT interval.
Inotropic effects of BAY y 5959. Although all isovolumetric
indexes have some limitations, in that they can be affected by
heart rate, preload and afterload, it is noteworthy that the
increases in dP/dt max and in (dP/dt)/DP40 occurred in most
cases despite slight reductions in heart rate and LV end-
diastolic pressure. This is good evidence for an increase in
myocardial contractility, a conclusion further supported by the
leftward shift of the end-systolic pressure-volume data (Figs. 1
and 3). The effects on dP/dt max appeared relatively linear
within a plasma concentration range of 20 to 100 mg/liter (Fig.
2). Few effects were observed at an infusion rate ,1.0 mg/kg
per min. At doses that overlap between studies 1 and 2 (1.0, 2.0
and 3.0 mg/kg per min), the responsiveness of the failing
ventricle to BAY y 5959 appeared to be well maintained. This
observation is consistent with data recently reported in con-
scious dogs with heart failure (11). The mean changes in
end-diastolic and end-systolic volume indexes observed at
doses of 2.0 and 3.0 mg/kg per min were also of the same
magnitude in studies 1 and 2, although ejection fraction tended
to improve more in patients with preserved systolic function.
There appeared to be no significant effect on the rate of
myocardial relaxation, estimated by T1 (9), although the
beginning of relaxation was probably delayed, given the pro-
longation in the QT interval. In light of the multiple feedback
mechanisms that regulate sarcoplasmic reticulum function and
Figure 3. Typical changes in pressure–volume loop observed in pa-
tients with moderate to severe heart failure during infusion of BAY y
5959 at a dose of 3.0 mg/kg per min (top) and at a dose of 4.5 mg/kg per
min (bottom). Although both doses decreased end-systolic volume,
4.5 mg/kg per min produced a substantial increase in systolic pressure.
Table 3. Hemodynamic Data: Study 2
Mean Baseline
(n 5 20)
D Dose 1.0
(n 5 5)
D Dose 2.0
(n 5 5)
D Dose 3.0
(n 5 5)
D Dose 4.5
(n 5 5)
D Global
(n 5 20)
HR (beats/min) 84.7 6 16.2 211.1 6 7.8* 26.2 6 4.8* 28.9 6 7.7 211.9 6 7.2* 29.5 6 6.8‡
LVEDP (mm Hg) 29.3 6 8.5 28.6 6 6.7* 22.0 6 7.0 27.0 6 2.9† 0.2 6 3.9 24.3 6 6.2†
LVSP (mm Hg) 124.5 6 21.3 23.7 6 10.2 6.2 6 10.3 9.5 6 11.1 23.3 6 9.7† 8.8 6 13.7†
Mean AoP (mm Hg) 94.4 6 13.0 23.3 6 6.2 1.3 6 9.6 0.2 6 11.6 7.4 6 8.0 1.4 6 9.2
dP/dt max (mm Hg/s) 1,005 6 266 10 6 103 166 6 152 255 6 185* 462 6 107‡ 223 6 212‡
(dP/dt)/DP40 (s21) 13.4 6 4.0 2.1 6 1.4* 2.6 6 3.9 5.8 6 3.6 7.5 6 2.4† 4.5 6 3.6‡
T1 (ms) 73.6 6 14.3 2.7 6 6.2 21.9 6 12.3 27.2 6 11.0 14.4 6 12.3 2.0 6 12.8
QTc (ms) 478 6 50 18 6 26 49 6 32* 79 6 69 83 6 44* 57 6 50‡
*p , 0.05. †p , 0.01. ‡p , 0.001. Data are expressed as mean value 6 SD. Abbreviations as in Table 1.
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the sensitivity of contractile proteins to calcium, one can only
speculate about the lack of slowing in relaxation rate. One
hypothesis, which could be verified in isolated myocardium, is
that BAY y 5959 does not cause a net increase in intracellular
calcium stores, the increased influx in systole being compen-
sated by an efflux of similar magnitude during each diastole.
Furthermore, LVEDP decreased, and the diastolic pressure-
volume relation tended to be shifted downward. Here, also,
several factors such as changes in right ventricular size due to
the inotropic stimulation could explain this observation (12),
and mean diastolic wall stress decreased significantly in both
groups at the dose of 3.0 mg/kg per min. Thus, although BAY
y 5959 promotes calcium entry into the myocardium, there was
no evidence for an impairment in diastolic function similar to
that seen in other types of calcium overload (e.g., ischemia,
toxic doses of digoxin).
Effects on global left ventricular pump function. In pa-
tients with preserved LV function, the mean cardiac index was
normal at baseline (3.6 liters/min per m2). In this setting, BAY
y 5959 produced only insignificant changes in cardiac index;
stroke volume increased slightly but, because of the decrease in
heart rate, overall output remained unchanged. This observa-
tion is not surprising as it is well known (13) that at rest, in the
absence of pump failure, cardiac output is more dependent on
venous return than on myocardial contractility. One could have
expected, however, to observe a relatively large decrease in
LVEDP, because with inotropic stimulation the ventricle is
expected to achieve similar or greater stroke work at a lower
end-diastolic volume. Only slight decreases in end-diastolic
volume and pressure were seen at doses of 2.0 and 3.0 mg/kg
per min (p 5 NS). It is possible that at these infusion rates,
inotropic stimulation is still very modest when compared, for
example, with sympathetic stimulation during exercise and that
the decrease in heart rate also contributed to minimize the
changes in LVEDP.
In contrast, in patients with heart failure, cardiac index was
slightly reduced at baseline (2.7 liters/min per m2) and in-
creased at infusion rates of 2.0 and 3.0 mg/kg per min (by 23 6
13% and 11 6 6%, respectively) despite the slight bradycardia.
At doses between 1.0 and 3.0 mg/kg per min, LVEDP also
decreased, but again the inotropic stimulation was relatively
modest, as estimated by the percent increase in dP/dt max, and
there was little change in afterload, as assessed by mean aortic
pressure, calculated systemic vascular resistance or mean sys-
tolic wall stress. It is therefore not surprising that at this level
of inotropic stimulation the overall hemodynamic benefit was
less than with drugs like dopamine or amrinone, which com-
bine positive inotropic and vasodilator properties. Moreover,
at the highest infusion rate, the increase in cardiac index was
no longer significant (8 6 13%) and there was a substantial
increase in LV systolic pressure (Table 3; Fig. 3, bottom).
These findings suggest that, at this infusion rate, some degree
of smooth muscle selectivity is lost and that BAY y 5959, like
the classic calcium agonist BAY k 8644, may start producing
some systemic vasoconstriction. Indeed, systemic vascular re-
sistance reached a minimum at the 2.0-mg/kg per min rate
(214 6 9%; p , 0.05), was insignificantly reduced at 3.0 mg/kg
per min (27 6 11%; p 5 NS) and started to rise at 4.5 mg/kg
per min (15 6 13%; p 5 NS).
Effects on heart rate and QT interval. At doses beginning
at 2.0 mg/kg per min, BAY y 5959 produced a mild reduction
in sinus rhythm. Although agents that prolong action potential
may slower the sinus rate, Sato et al. (14) observed in dogs that
the bradycardia in response to BAY y 5959 was abolished after
ganglionic blockade. This finding suggests a role of the barore-
ceptor reflex in the bradycardia, but such a conclusion would
require confirmation in humans. By its pharmacologic action,
BAY y 5959 increased the action potential duration; hence, the
QT/QTc interval would also be expected to increase in vivo. In
theory, this corresponds to a class III antiarrhythmic effect.
However, QT prolongations have been linked to afterpotential
generation and torsade de pointes, a life-threatening ventric-
ular arrhythmia. Female patients and patients with congestive
heart failure are, among others, particularly at risk for this
complication (15). In the present study, no proarrhythmia was
observed, and it also appeared that the QT prolongation
tended to reach a plateau faster than the increase in contrac-
tility (Fig. 2). However, the number of patients was very small
and, given the risk observed with all agents that prolong the
QT interval, careful monitoring will continue to be necessary
and further studies will be needed to assess the electrophysi-
ologic effects of this class of agents in patients.
In summary, the new calcium promoter BAY y 5959 exhibits
bradycardic and positive inotropic properties that are pre-
served in patients with heart failure. The optimal response—
combining bradycardia, reduced preload and improved cardiac
output—appeared to be achieved at a dose of ;2.0 mg/kg per
min. The impact of QT prolongation with regard to potential
antiarrhythmic or proarrhythmic effects is unclear at this time.
This compound, which appeared to be well tolerated and
Figure 4. Relation between total dose of BAY y 5959 administered
and the area under the curve (AUC) in patients with or without heart
failure. BAY y 5959 exhibits linear pharmacokinetics that does not
appear to be affected by the presence of heart failure. l 5 liter.
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exhibited predictable kinetics, deserves further clinical evalu-
ations in patients with heart failure.
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